Hydroxychloroquine (HCQ) for Recurrent Pregnancy Loss
Overview
Recurrent pregnancy loss (RPL) defined as 3 or more pregnancy losses affects approximately 3% of couples trying to achieve parenthood. Most cases of RPL are unexplained and have no effective treatment to improve the chance of a live birth. Exciting indications for using Hydroxychloroquine (HCQ) include: Malaria profylaxis and treatment, systemic and discoid lupus erythematosus (SLE) and rheumatoid athritis (RA). HCQ has been reported to have the following properties (anti-thrombotic, vascular-protective, immunomodulatory, improving glucose tolerance, lipid-lowering, and anti-infectious). There is no data concerning the benefit of HCQ in RPL. Administration for other indications provides extensive safety data during pregnancy. This study has the potential to establish support for a new treatment option for unexplained RPL.
Full Title of Study: “Hydroxycloroquin (Plaquenil) Behandling af Gentagne Graviditetstab (Abortus Habitualis) – et Randomiseret, Dobbeltblindet, Placebo Kontrolleret Studium”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Study Primary Completion Date: January 2022
Interventions
- Drug: Hydroxychloroquine
- One tablet a day from inclusion until end of pregnancy or gestational age 28
- Drug: Hydroxychloroquine placebo
- One tablet a day from inclusion until end of pregnancy or gestational age 28
Arms, Groups and Cohorts
- Experimental: Hydroxychlorochine HCQ
- Women in the experimental arm will take 200 mg HCQ tablets every day, starting minimum 2 months (recommended 3-6) prior to conception and continuing until 28 weeks of pregnancy or until the pregnancy is over.
- Placebo Comparator: Hydroxychlorochine HCQ Placebo
- Women in the experimental arm will take 200 mg HCQ placebo tablets every day, starting minimum 2 months (recommended 3-6) prior to conception and continuing until 28 weeks of pregnancy or until the pregnancy is over.
Clinical Trial Outcome Measures
Primary Measures
- Live birth
- Time Frame: At delivery
Secondary Measures
- Live birth after exclusion of patients with a chromosomal abnormal pregnancy loss, extrauterine pregnancy loss, intended abortion or patients with insufficient intake of study medicine
- Time Frame: At delivery
- Birth weight
- Time Frame: At delivery
- Gestational age
- Time Frame: up to at delivery
- Admittance to neonatal unit
- Time Frame: Within 28 days of delivery
- Immunological status
- Time Frame: Up to two years after end of study
- Measuements of celllur and humoral immunity
Participating in This Clinical Trial
Inclusion Criteria
1. ≥ 4 confirmed consecutive pregnancy losses prior to gestational age 22+0 in women with unexplained RPL 2. ≥ 3 confirmed consecutive pregnancy losses prior to gestational age 22+0 in women with unexplained RPL with minimum one second trimester loss. Exclusion Criteria:
1. Age below 18 years or above 39 at inclusion 2. Abnomal uterine anatomi at hysterosalpingography/hysteroscopy or hydrosonography 3. Chromosomal abnormalities within the couple 4. Menstrual cycle below 23 days or above 35 days 5. Lupusantikoagulans positivity or immunoglobulin (Ig)G/IgM anticardiolipinantibodies (≥10 GPL kU/l at Rigshospitalets Laboratorium) or plasma homocystein ≥25 mikrogr./l at repeated measurement with 12 weeks interval. 6. HIV or Hepatitis B or C positive 7. Psoriasis, retinopathy og serious imparied hearing (Contraindications for HCQ) 8. Chronic disease that lead to intake of immunemodulatory drugs or potentially pregnancy toxic agents 9. Hemoglobin ≤ 6.5 mmol/L, leukocytes <3.5 E9/L, platelets <145 E9/L at inclusion 10. Previous treatment with HCQ in pregnancy 11. >1previous live birth 12. previous participation in this trial
Gender Eligibility: Female
Minimum Age: 18 Years
Maximum Age: 39 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Rigshospitalet, Denmark
- Provider of Information About this Clinical Study
- Principal Investigator: Henriette Svarre Nielsen, MD, DMSc, Consultant, Head of Recurrent Pregnancy Loss Unit, Associate Professor – Rigshospitalet, Denmark
- Overall Contact(s)
- Henriette Svarre Nielsen, MD, DMSc, +4535457515, henriette.svarre.nielsen@regionh.dk
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.